Annai Systems, a leading genomic data solutions company, recently announced it will provide its STARPlatform next-generation sequencing data management solution to the Glioma Longitudinal AnalySiS (GLASS) consortium. The GLASS consortium consists of neuropathologists, clinicians, scientists, and bioinformaticians from leading institutions across the globe. Annai Systems’ STARPlatform will enable GLASS to manage whole exome and genome sequencing data across multiple research centers.
Annai Systems Provides STARPlatform NGS Data Management Solution to Global Consortium Focused on Tumor Research
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) recently announced the availability of a new application for the companion diagnostic associated with the use of Tarceva® for the treatment of certain patients with non-small cell lung cancer (NSCLC). The Roche cobas® EGFR Mutation Test v2 is the first blood-based test approved for clinical use in the U.S. to detect certain epidermal growth factor receptor (EGFR) gene mutations in NSCLC patients. LabCorp played a key role in making the test available upon approval by the U.S. Food and Drug Administration (FDA) and is the only national laboratory currently offering the test.
Agilent Technologies to Acquire Assets of iLab Solutions, Leader in Cloud-Based Laboratory Management Software
Agilent Technologies Inc. (NYSE: A) and iLab Solutions, LLC recently announced they have signed a definitive agreement under which Agilent will acquire substantially all of the assets of iLab, the market leader in cloud-based solutions for core laboratory management. The acquisition includes iLab’s technology, intellectual property and product portfolio, as well as employee talent.
Guardant Health and Oncotest-Teva Announce Exclusive Distribution and Marketing Partnership for Guardant360 in Israel
Guardant Health, the leader in comprehensive liquid biopsy, announced a distribution and marketing partnership with Oncotest-Teva, [a subsidiary of Teva Pharmaceutical Industries Ltd. in Israel]. The partnership will make Guardant360®, Guardant Health’s groundbreaking, non-invasive genomic sequencing test for patients with advanced cancer, widely available to oncologists and patients in Israel.
Novigenix SA recently announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with tumor biomarkers for the early detection of colorectal cancer (CRC).